Keyword: Esperion Therapeutics
Esperion has the 52-week safety data it needed for its cholesterol therapy bempedoic acid, clearing the way for regulatory filings next year.
A phase 3 trial has found that adding Esperion’s bempedoic acid to Zetia lowers LDL cholesterol more than the statin alone.
Esperion's bempedoic acid is continuing its roll, lowering LDL cholesterol in patients with atherosclerosis.
Esperion’s phase 3 results of bempedoic acid showed it lowered cholesterol levels, but 13 deaths were also reported, causing shares to slide.
Esperion's bempedoic acid lowered LDL levels by 30% in patients on a PCSK9 blocker for cholesterol.
A 12-week course of Esperion's bempedoic acid lowered patients' LDL cholesterol by 23%.
The regimen lowered LDL cholesterol by 64%, a bigger drop than the combination of Zetia and Lipitor has achieved in other studies.